PDS Biotech announces FDA clearance of IND apprlication for Versamune MUC1 combo
PDS Biotechnology (PDSB) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application filed in ...
GlobalData on MSN4d
PDS Biotechnology commences trial for head and neck squamous cell carcinoma
PDS Biotechnology has commenced the randomised, multi-centre Phase III clinical trial, VERSATILE-003, to assess the efficacy ...
Morningstar3d
PDS Biotech Leadership to Participate in March Conferences
PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy ...
Nasdaq7d
PDS Biotechnology Corporation Initiates VERSATILE-003 Phase 3 Clinical Trial for HPV16-Positive Head and Neck Cancer
PDS Biotech launches VERSATILE-003 Phase 3 trial to evaluate Versamune® HPV with pembrolizumab for treating HPV16-positive head and neck cancer. PDS Biotechnology Corporation has announced the ...
PDS Biotechnology (NASDAQ:PDSB) Receives “Buy” Rating from HC Wainwright
HC Wainwright restated their buy rating on shares of PDS Biotechnology (NASDAQ:PDSB – Free Report) in a research note published on Friday,Benzinga reports. They currently have a $21.00 target price on ...
Morningstar1d
PDS Biotechnology Corp PDSB
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Nasdaq7d
PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer
PRINCETON, N.J., March 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy ...